Lars Lannfelt, inventor of the approved (in the U.S. and elsewhere) Alzheimer's medicine Leqembi, describes how the drug works and shares his understanding of Alzheimer's disease

Professor Lannfelt recounts the history of researching amyloid beta and explains why he thinks it is vital to target amyloid beta protofibrils to have an impact on the disease. Plus, the future of treating Alzheimer's earlier and getting more of the medicine into the brain, both of which BioArctic is currently working on.